NetWellness is a global, community service providing quality, unbiased health information from our partner university faculty. NetWellness is commercial-free and does not accept advertising.
Wednesday, January 18, 2017
Can you explain to me the debate of using Atrovent for pulmonary diseases? I know it is a generally localized Muscarinic antagonist. Is the debate dealing with the decreased mucous secretion and dilated bronchioles causing more exposure to allergens?
I`m not aware of any debate. Atrovent is a bronchodilator with anticholinergic activity. Several studies have shown excellent action on patients with COPD where it is often considered first line therapy. For asthma it also a bronchodilator but is mainly used as adjunctive therapy.
Mitchell C Rashkin, MD
Professor of Medicine
College of Medicine
University of Cincinnati